{
  "id": 4773032,
  "title": "Is Merck Stock Outperforming the Nasdaq?",
  "url": "https://urgent.news/2026/08/30/is-merck-stock-outperforming-the-nasdaq",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-30T19:15:34.000Z",
  "source": {
    "name": "Yahoo Finance",
    "slug": "yahoo-finance",
    "url": "https://finance.yahoo.com/markets/stocks/articles/merck-stock-outperforming-nasdaq-191534975.html"
  },
  "original_language": "en",
  "account": "Merck & Co., Inc., a global research-driven biopharmaceutical company headquartered in Rahway, New Jersey, has been making waves in the stock market. Known as MSD outside the U.S. and Canada, Merck operates through two primary business segments: Pharmaceuticals and Animal Health. With a market capitalization of $297 billion, Merck is classified as a mega-cap stock. The company's pharmaceutical portfolio encompasses oncology, vaccines, cardiometabolic diseases, infectious diseases, and several other therapeutic areas. This broad range of products underpins Merck's position as a dominant force in the drug manufacturers industry.\n\nMerck's strength lies in its dominant oncology franchise, a broad vaccine portfolio, and an expanding pipeline of newer medicines. The company's recent breakthrough, a personalized mRNA cancer vaccine in combination with its Keytruda, has not only bolstered its oncology pipeline but also offers a potentially significant growth opportunity, especially as Keytruda approaches patent expiration.\n\nDespite a 5.5% dip from its 52-week high of $156.92, Merck's stock has shown remarkable resilience, with a 23.7% increase over the past three months. This performance significantly outpaces the Nasdaq Composite's 1.9% decline during the same period. Over the longer term, Merck has outperformed the broader market. The stock surged 78.3% in the past 52 weeks, while the Nasdaq Composite delivered a 21.6% return. In 2026, Merck's stock has risen by 40.9%, outpacing the index's 13.6% growth.\n\nThe company's recent announcement of a significant Phase 3 win for their personalized mRNA cancer vaccine further solidifies Merck's position in the market. This development has not only strengthened Merck's oncology pipeline but also presents a potentially important new growth opportunity as Keytruda approaches patent expiration. Consequently, Wall Street's sentiment towards Merck is moderately optimistic, with the overall consensus rating from the 28 analysts covering the stock at a Moderate Buy. Merck's stock currently trades above the mean price target of $148.30.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}